Advertisements

Jusgo Gel

Quick links to important sections

Jusgo Gel

Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Jusgo Gel

Property Description
Active Ingredients Diclofenac, Methyl Salicylate, Menthol, Linseed Oil
Form Gel (Topical Preparation)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID) and Topical Analgesic Combination
Common Use Localized relief from musculoskeletal pain and stiffness
Origin Semi-Synthetic Combination

What Type of Medicine is Jusgo Gel?

Jusgo Gel is defined as a topical medication, specifically a gel formulation for external use only, which is clinically recognized for its analgesic properties. Pharmacologically, it belongs to the class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and is distinctly characterized as a multi-ingredient combination product. The combination format provides a differentiated approach to pain management compared to simpler, single-component topical NSAIDs.

Active Components and Compositional Identity

The gel is a multi-ingredient formulation centered around four active components: Diclofenac, which is typically present as the sodium or diethylamine salt, alongside Methyl Salicylate, Menthol, and Linseed Oil (Oleum Lini). Diclofenac, a phenylacetic acid derivative, serves as the primary component, providing the core anti-inflammatory effect. The formulation’s unique feature lies in the synergistic inclusion of Menthol and Methyl Salicylate, which function as topical analgesic and counter-irritant agents. This approach of combining a core NSAID with established counter-irritants is supported by pharmacological studies.

The General Purpose of This Topical Combination

The general purpose of Jusgo Gel is to offer highly targeted localized relief from symptoms of discomfort associated with musculoskeletal issues, such as stiffness, swelling, and pain in muscles and joints. A typical use scenario involves application to an area affected by temporary joint or muscle soreness. The overall effect is achieved through a robust, dual high-level mechanism: the Diclofenac component works to reduce the underlying inflammation, while the combined action of the Menthol and Methyl Salicylate provides an immediate, noticeable cooling and warming sensation on the skin's surface, accelerating symptomatic comfort.

Regulatory References

  1. NIH, Diclofenac Information
Advertisements

What side effects are possible with Jusgo Gel?

Possible Side Effects and Safety Information

The documented safety profile for this topical preparation is primarily characterized by reactions occurring at the application site, reflecting its localized use. According to regulatory safety classifications, reactions classified as common include application site dermatitis, pruritus (itching), erythema (redness), and pain or burning sensation. These local adverse reactions are frequently observed early in the course of treatment.

Adverse effects are categorized by System-Organ Class, with the Skin and subcutaneous tissue disorders being the primary focus. Rarer effects observed in this system include photosensitivity reactions, generalized skin rash, and bullous dermatitis. Effects relating to Immune system disorders and Respiratory, thoracic and mediastinal disorders cover the very rare risks of systemic hypersensitivity reactions, angioedema, and asthma/bronchospasm, which are linked to the NSAID component.

Serious adverse reactions, such as anaphylaxis, are listed as a very rare risk. Official regulatory constraints mandate specific limitations. The product is contraindicated during the third trimester of pregnancy due to class risk and must not be used on broken skin, open wounds, or in individuals with documented hypersensitivity to diclofenac, aspirin, or other NSAIDs. Furthermore, caution is required regarding application over large skin areas or for prolonged periods, as this may increase the risk of systemic effects.

Advertisements

Overdose and Emergency Response

The risk of overdose from this topical combination product is officially considered unlikely when used correctly, due to the low systemic absorption of its active ingredients. However, the potential for systemic toxicity increases significantly in cases of accidental oral ingestion or excessive dermal use over large areas. Overdose may present with documented clinical findings affecting the central nervous system, gastrointestinal tract, and metabolic systems.

Officially listed symptoms can include nausea, vomiting (potentially bloody), epigastric pain, confusion, dizziness, tinnitus, or rapid breathing (hyperpnea). Regulators explicitly warn that systemic NSAID toxicity carries a risk of serious, potentially fatal, gastrointestinal events such as bleeding and ulceration, a risk that is greater in elderly patients. Furthermore, the ingestion of the Methyl Salicylate component by a young child is explicitly documented as dangerous.

Immediate medical attention is required for accidental ingestion resulting in significant systemic effects or if a severe anaphylactic reaction occurs. If an excessive amount of gel is accidentally applied, the official guidance is to wipe the excess off the skin. Management is based on supportive and symptomatic treatment, as no specific antidote is known for the Diclofenac component. If collapse or seizures occur, emergency services must be contacted.

Advertisements

Therapeutic Uses of Jusgo Gel

What Jusgo Gel Treats: Main Uses and Benefits

Jusgo Gel is commonly used across therapeutic domains where short-term symptomatic assistance is needed for various musculoskeletal complaints. It helps address symptom clusters that may become intense or disruptive, such as those associated with sprains, muscle strains, general backaches, lumbago, fibrositis, and localized discomfort from arthritis. The product is applied in scenarios where additional management of discomfort is required for conditions involving acute or episodic changes. It provides supportive relief when symptoms create noticeable physiological strain.

“This application supports the patient during difficult episodes by easing distress and may contribute to improved day-to-day comfort, assisting with maintaining functional stability.”

Quick Fact: Relief for Joint and Muscle Stiffness

This gel is commonly used when symptoms intensify, particularly joint stiffness, and supportive relief is needed. It helps address symptoms that interfere with daily functioning, offering symptomatic support in conditions characterized by periods of heightened discomfort.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Regulatory documents define strict rules governing who can use Jusgo Gel, primarily based on the presence of Diclofenac (an NSAID) and other analgesic components.

Classification Official Eligibility Rule Restriction/Status
Approved Age Adults and adolescents aged 14 years and over. Permitted under labeled conditions.
Pediatric Use Children and adolescents under 14 years of age. Contraindicated (not approved).
Allergy Risk History of asthma, urticaria, or allergic-type reactions after taking aspirin or any other NSAID. Contraindicated (absolute prohibition).
Pregnancy Stage Women in the third trimester (starting at 30 weeks gestation). Contraindicated (absolute prohibition).
Skin Condition Application to damaged or non-intact skin (e.g., open wounds, eczema). Prohibited (application site restriction).

Eligibility also requires caution in specific patient populations due to the potential for systemic absorption of the active ingredients, even if low. Use requires monitoring in elderly patients and those with severe renal or hepatic impairment or a history of severe heart failure.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile for Jusgo Gel based on the systemic absorption potential of its primary component, Diclofenac, a Nonsteroidal Anti-inflammatory Drug (NSAID). These interactions are classified into pharmacokinetic and pharmacodynamic patterns, requiring specific restrictions or careful monitoring.


Documented Interaction Patterns

Pharmacodynamic Reinforcement of Bleeding Risk: Co-administration with oral anticoagulants (e.g., Warfarin), anti-platelet agents (e.g., Aspirin), and Selective Serotonin Reuptake Inhibitors (SSRIs) is documented to increase the risk of serious bleeding events due to additive effects on hemostasis. Frequent monitoring of the International Normalized Ratio (INR) may be required with anticoagulants.

Pharmacodynamic Interference with Efficacy: The Diclofenac component may reduce the therapeutic efficacy of certain diuretics (e.g., Furosemide) and antihypertensive medicines (e.g., ACE Inhibitors, ARBs), and increases the risk of acute renal dysfunction.

Pharmacokinetic Modification: Strong CYP2C9 inhibitors (e.g., Voriconazole) cause a documented increase in the plasma concentration and total systemic exposure (AUC) of Diclofenac. Conversely, CYP2C9 inducers may decrease exposure.

Interaction-Related Restrictions: Use with other systemic NSAIDs is generally not recommended. The use of NSAIDs is formally contraindicated for the relief of pain in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery.

Population-Specific Note: Interactions, particularly those involving bleeding risk and kidney injury, are documented as having a significantly higher severity in elderly patients.

Advertisements

Mechanism of Action

Molecular Blockade of the Inflammatory Cascade

The mechanism is centered on the competitive inhibition of Cyclooxygenase (COX) enzymes by Diclofenac and Methyl Salicylate, which modulate local inflammation. By suppressing the synthesis of Prostaglandins, the gel engages a mechanism that leads to a lowered concentration of pro-inflammatory mediators and decreased edema. This action focuses on modulating the eicosanoid pathway to influence the eicosanoid profile.


Rapid Modulation of Peripheral Sensory Signaling

The formulation also operates within the domain of peripheral nociceptive signaling via the action of Menthol on the TRPM8 ion channel. Menthol acts as an agonist, generating a rapid thermal sensory signal that overrides the slower pain transmission signals. This sensory distraction alters the transmission of nociceptive signals via sensory distraction, causing rapid modification of peripheral nerve signaling.


Mechanistic Synergy and Localized Flux Enhancement

This combination product exerts its action through synergy and enhanced transdermal flux. The action of Menthol as a percutaneous absorption promoter increases the local concentration of the anti-inflammatory component (Diclofenac) in deeper tissues. This coordinated mechanism modulates overactive physiological responses by delivering targeted molecular action.

Advertisements

Dosage and Administration Information

How to Use Jusgo Gel — Official Administration Guidelines

Administration Scope and Route

Jusgo Gel is designated for topical (cutaneous) administration and is strictly intended for external use only. The general administration regimen involves applying a specific measure of gel to the area of discomfort 3 to 4 times daily.

Standard Dosing and Quantity

The typical single application requires dispensing a strip of gel measuring between 4 cm and 8 cm in length, which is equivalent to approximately 2 to 4 grams of product. Across all applications within a 24-hour period, the total amount of any topical diclofenac product should not exceed 32 grams. No preparation or dilution steps are specified; the product is designed for direct application.

Age-Group Rules and Procedural Constraints

The standard adult dosing schedule applies to adolescents who are 14 years of age and older. However, a specific modified regimen is outlined for children aged 6 to 12 years, requiring a reduced single dose of 2 grams (a 4 cm strip) and limiting the frequency to no more than 2 times a day. The official administration protocol instructs that the measured dose must be gently rubbed into the skin until absorbed. It is emphasized that the gel must be applied only to healthy, unbroken skin, and the use of occlusive (airtight) dressings over the treated area is not recommended.

Use Protocol and Duration

The labeled instructions constrain the period of self-treatment, stating that use should not extend beyond 7 to 10 days without medical review.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the published research that has evaluated the drug and the study findings documented in controlled settings. The active ingredients include Diclofenac, Linseed Oil, Menthol, and Methyl Salicylate, which are investigated for their localized topical activity.


Initial Findings and Assessments

Studies evaluated the drug's activity in laboratory models. The primary studies investigated the study's impact on patient-reported pain scores. The core formulation is studied for conditions such as acute musculoskeletal pain and pain associated with osteoarthritis of the joints.

  • One large-scale trial reported the results of the assessment of symptoms over a 12-week period. This trial focused on adults (age 18–65) with chronic, non-specific pain.
  • A study examined specific laboratory markers in participants, assessing changes in inflammatory parameters.

Combination Use Investigations

Research has investigated the assessment of nerve pain severity when the drug is used in combination compared to monotherapy. This research used a primary outcome measure such as the Brief Pain Inventory (BPI) score, which relies on participant self-reporting of pain.

  • A Phase 3 trial assessed the combination for 8 weeks in participants with diabetic neuropathy. The investigation examined BPI scores from baseline to the end of the study period.
  • Research has also examined concurrent use with a healthy diet and monitored study parameters to see if lifestyle factors were correlated with study outcomes.

Specific Population and Formulation Studies

Studies investigated the assessment of migraine attack severity and frequency when using the new formulation. This study was conducted in a cohort of 400 individuals diagnosed with episodic migraine.

  • Studies assessed the time frame during which participants documented results at specific time points after treatment began. The median time documented to a noticeable assessment change was 10 days in the primary study group.
  • Research examined the study outcomes reported by participants with mild kidney impairment, focusing strictly on the primary endpoints of the trial.
  • Trials assessed the primary outcomes reported by participants with pre-existing heart conditions.

Key Studies & References

  1. Guidance on the use of topical nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of acute and chronic pain
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Jusgo Gel (FAQ)


Q: How quickly does Jusgo Gel usually start working?

The official product information indicates that the formula includes components designed to activate a thermal sensory channel. This action, which involves a quick modification of peripheral sensory signals, can lead to a noticeable sensation on the skin shortly after application.


Q: Can Jusgo Gel be used on large areas of the body?

Official documents state that the product must not be used on extensive or large body areas. Use is typically limited to the affected localized body parts, as described in the administration guidelines.


Q: What happens if I forget to use Jusgo Gel?

Regulatory instructions define the protocol for a missed application: the next application should be resumed as soon as it is remembered, unless it is nearly time for the next scheduled application. If it is nearly time for the next application, the missed application is omitted, and the schedule is continued as usual. Regulatory information specifies that a double application must not be used.


Q: Is it normal to feel a warming or cooling sensation after applying Jusgo Gel?

The official product documentation indicates this sensation is linked to the mechanism of action. The active component Menthol activates a thermal sensory channel on the skin, which may result in a rapid cooling or warming sensation.


Q: Can Jusgo Gel cause general skin irritation?

According to official safety information, common application site adverse reactions include dermatitis, which may involve general skin irritation, redness (erythema), and itching (pruritus). Additionally, some non-active ingredients (excipients) in the formula have the potential to cause local skin reactions, as documented in regulatory safety information.


Q: Can I use Jusgo Gel if I have generally sensitive skin?

Regulatory eligibility documents only specify contraindications for known allergies to Diclofenac, aspirin, or other NSAIDs. However, regulatory documentation indicates that some non-active ingredients (excipients) in the gel have the potential to cause local skin reactions.


Q: Does using Jusgo Gel affect other non-medicated topical products (like lotions or sunscreens)?

Official documents caution against using occlusive (airtight) dressings or applying heat to the treated area, and patients are directed to wait a specific time before showering. While non-medicated products are not explicitly listed in interaction warnings, this general caution suggests limitations on what can be applied over the treatment area.


Q: Are there specific body parts (e.g., face, mucous membranes) where Jusgo Gel should not be used?

Official safety information describes the product as being for external use only. Application to non-intact skin is not permitted, nor should the gel come into contact with the eyes or mucous membranes, such as the nose or mouth.


Q: Why is Jusgo Gel sometimes recommended for [General condition/area]?

This topical preparation is classified as an NSAID combination. The formulation’s design aims to deliver the anti-inflammatory component to a localized area, potentially resulting in lower overall systemic exposure compared to oral NSAID forms.


Q: Can people who are allergic to certain dyes or preservatives use Jusgo Gel?

The drug is formally contraindicated in patients with a known hypersensitivity to the active components or to any of the excipients (inactive ingredients) listed in the official product documentation. This requirement for exclusion applies to any component, which includes dyes or preservatives in the formula.


Q: What is the difference in purpose between Jusgo Gel and a simple heat rub?

Jusgo Gel is classified as a combination product containing an NSAID. The component Diclofenac is documented to modulate inflammation, which is provided in addition to the localized symptomatic thermal sensation that simple heat rub products may offer.


Q: Why is it important to read the patient leaflet for Jusgo Gel?

The patient leaflet is required to contain all necessary safety constraints, contraindications, required warnings, and detailed instructions for proper use. Regulatory agencies expect patients to review this information before using the product.


Q: What should I do if I accidentally get Jusgo Gel in my eye?

Official instructions state that if the gel accidentally comes into contact with the eyes, rinsing immediately and thoroughly with water or saline is the protocol. If irritation persists after the advised timeframe, obtaining further review from a healthcare professional is documented as the next step.


Q: Can Jusgo Gel be used if I am trying to become pregnant or in the first/second trimester?

Regulatory documents state that NSAIDs may impair female fertility. The patient information indicates that discontinuation of the drug is a documented consideration when trying to conceive. Regarding the first and second trimesters, regulatory advice indicates that use is generally avoided unless clearly necessary, and the dose and duration should be maintained at the lowest and shortest levels possible.


Q: Is Jusgo Gel effective for treating nerve pain? (Based on research evidence)

Official research cited in regulatory reviews includes investigations of the drug in specific conditions involving nerve pain. This includes a Phase 3 trial that assessed the drug's use in participants with diabetic neuropathy.


Q: Do older adults need to be more careful when using Jusgo Gel?

Yes. Official documents define the need for caution in elderly patients due to a documented higher severity risk of systemic adverse events, such as gastrointestinal and kidney issues. This includes a greater risk for certain drug interactions.


Q: How long does the localized effect (analgesia) of a single application of Jusgo Gel typically last?

The rapid, noticeable sensation begins shortly after application due to the counter-irritant components. The anti-inflammatory component is used in a multiple-daily dosing regimen. This administration method supports the drug's overall therapeutic effect by ensuring continued action.


Q: Are the safety profiles for Jusgo Gel well-studied in different patient groups?

Clinical trials and regulatory reviews have investigated the drug in specific patient cohorts to establish its safety profile. These groups include adults within specific age ranges, as well as those with mild kidney impairment and specific pain conditions.


Q: Do studies suggest Jusgo Gel has a specific role in long-term discomfort management?

The product is generally described in official patient information as being 'not for long-term use.' Self-treatment is formally limited to short durations. Prolonged use requires consultation with a healthcare professional.


Q: Are there restrictions on using Jusgo Gel before or after a hot bath or shower?

Regulatory information indicates that the treated area should not be covered with a heating pad or tight dressing. The patient information also specifies avoiding showering or bathing for a specific period (typically at least one hour) after application.


Q: Are there specific limitations on how long Jusgo Gel can be used for adolescents aged 14 and over?

The instructions state that for self-treatment of common conditions, use should not extend beyond a specific time frame, typically 7 to 10 days, without consulting a healthcare professional.

Advertisements

How should Jusgo Gel be stored and disposed of?

How to Store and Dispose of Jusgo Gel

Jusgo Gel must be stored strictly according to the following official regulatory requirements to maintain its stability and effectiveness:

Storage Requirements

Condition Requirement
Temperature Store at a temperature not exceeding 30 C and keep from freezing.
Environmental Protect from direct sunlight and excessive heat; store in a dry place.
Container Keep the container tightly closed and store in its original container.
Child Safety Keep out of the reach of children.

Disposal Instructions

Disposal of unused or expired product must follow local requirements. It is prohibited to discharge the gel into drains, water courses, or onto the ground as this product must not be released into the aquatic environment. Any waste material should be disposed of at an approved waste facility.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Jusgo Gel found in:

A-Z Index: